23 Jul, 2026
According to Straits Research, the global digital biomarkers market valued at $4.43 billion in 2025, is projected to grow from $5.3 billion in 2026 to $22.3 billion by 2034 at a CAGR of 19.67% during the forecast period 2026–2034.
Digital Biomarkers are the data used to track anatomical, psychological, and behavioral changes in the human body using various sensors, Machine Learning (ML), and Artificial Intelligence (AI) techniques, making the data accessible to the wearer and other concerned users. The digital biomarkers currently used in the healthcare industry are the primary contributors to the significant data insights currently available. They assist in analyzing existing and anticipated health conditions and adverse situations.
The devices are available in a variety of forms, including those that are wearable, portable, digestible, and implantable. The oxygen saturation (SpO2) monitor and the heart rate monitor are two of the most common features found in consumer wearables. These monitors are essential for tracking heart and lung biostatistics to identify and warn users of adverse reactions. According to the CDC, cardiovascular disease is the leading cause of death in the United States, accounting for more than 960,000 deaths annually. The discovery of digital biomarkers greatly assists patients with chronic diseases.
The increasing use of digital biomarkers in diabetes, respiratory diseases, cardiovascular diseases, and sleep disorders is a significant market driver. Digital technologies have led to the increased adoption of handheld and wearable digital devices, which comprise a large portion of the digital biomarker market. Health informatics is expanding the global market for digital biomarkers. Digital biomarkers provide personalized, cost-effective care. The rapid evolution of telecommunications and IT infrastructure is also driving the market for digital biomarkers. Rising government and corporate investments in healthcare digitalization and smart hospitals are expected to boost global demand for digital biomarkers.
Wearable devices are the industry's second-biggest innovation after Bluetooth headsets. Google Glass, Apple Watch, Fitbit, MotivRing, and Oculus Rift are used in healthcare. The increased prevalence of wearable devices in healthcare is due to global health self-awareness, the rise in patients, and the increased use of technology in daily life. Many Google Play and iOS apps monitor sleep, heart rate, and movement. A recent survey found that 80% of developed and 82% of developing countries use smartphones.
Due to the rapid advancement of technology, companies are developing an increasing number of digital biomarkers; consequently, it will likely become an attractive investment segment in the future. With the increasing acceptance of data and devices, an increasing number of companies are investing in the production of digital biomarkers. The Centre for Disease Control and Prevention (CDC) discovered that notifications for Atrial Fibrillation on a particular smartwatch matched a patient's actual ECG 84 percent of the time, thereby reducing the mortality risk of individuals. Consequently, smartwatches and other consumer wearables that monitor multiple physiological factors of the human body are gaining popularity.
Asia-Pacific region held the largest share of the digital biomarkers market because governments emphasized improving healthcare infrastructure, the proliferation of smart devices such as smartphones, and the presence of a large pool of patients. The region held a significant share of the digital biomarker market because of North America's high penetration of smartphones and wearable devices. This can be attributed to the growing prevalence of lifestyle-related diseases, which, in turn, encourages consumers to monitor their vital signs for a better understanding of their current and future health conditions.
sales@straitsresearch.com